Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy
Patients affected by inflammatory bowel disease (IBD) have a two-fold higher risk of developing colorectal cancer (CRC) than the general population. IBD-related CRC follows a different genetic and molecular pathogenic pathway than sporadic CRC and can be considered a complication of chronic intestin...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/8/2389 |
| _version_ | 1797606021251727360 |
|---|---|
| author | Olga Maria Nardone Irene Zammarchi Giovanni Santacroce Subrata Ghosh Marietta Iacucci |
| author_facet | Olga Maria Nardone Irene Zammarchi Giovanni Santacroce Subrata Ghosh Marietta Iacucci |
| author_sort | Olga Maria Nardone |
| collection | DOAJ |
| description | Patients affected by inflammatory bowel disease (IBD) have a two-fold higher risk of developing colorectal cancer (CRC) than the general population. IBD-related CRC follows a different genetic and molecular pathogenic pathway than sporadic CRC and can be considered a complication of chronic intestinal inflammation. Since inflammation is recognised as an independent risk factor for neoplastic progression, clinicians strive to modulate and control disease, often using potent therapy agents to achieve mucosal healing and decrease the risk of colorectal cancer in IBD patients. Improved therapeutic control of inflammation, combined with endoscopic advances and early detection of pre-cancerous lesions through surveillance programs, explains the lower incidence rate of IBD-related CRC. In addition, current research is increasingly focused on translating emerging and advanced knowledge in microbiome and metagenomics into personalised, early, and non-invasive CRC screening tools that guide organ-sparing therapy in IBD patients. This review aims to summarise the existing literature on IBD-associated CRC, focusing on new insights into the alteration of the intestinal barrier and the interactions with the gut microbiome as the initial promoter. In addition, the role of OMIC techniques for precision medicine and the impact of the available IBD therapeutic armamentarium on the evolution to CRC will be discussed. |
| first_indexed | 2024-03-11T05:09:28Z |
| format | Article |
| id | doaj.art-c901dbff6ea94fe6a459f035d0368ee8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T05:09:28Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c901dbff6ea94fe6a459f035d0368ee82023-11-17T18:40:16ZengMDPI AGCancers2072-66942023-04-01158238910.3390/cancers15082389Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing TherapyOlga Maria Nardone0Irene Zammarchi1Giovanni Santacroce2Subrata Ghosh3Marietta Iacucci4Department of Public Health, University Federico II of Naples, 80131 Naples, ItalyDepartment of Medicine, University College of Cork, T12 R229 Cork, IrelandDepartment of Medicine, University College of Cork, T12 R229 Cork, IrelandDepartment of Medicine, University College of Cork, T12 R229 Cork, IrelandDepartment of Medicine, University College of Cork, T12 R229 Cork, IrelandPatients affected by inflammatory bowel disease (IBD) have a two-fold higher risk of developing colorectal cancer (CRC) than the general population. IBD-related CRC follows a different genetic and molecular pathogenic pathway than sporadic CRC and can be considered a complication of chronic intestinal inflammation. Since inflammation is recognised as an independent risk factor for neoplastic progression, clinicians strive to modulate and control disease, often using potent therapy agents to achieve mucosal healing and decrease the risk of colorectal cancer in IBD patients. Improved therapeutic control of inflammation, combined with endoscopic advances and early detection of pre-cancerous lesions through surveillance programs, explains the lower incidence rate of IBD-related CRC. In addition, current research is increasingly focused on translating emerging and advanced knowledge in microbiome and metagenomics into personalised, early, and non-invasive CRC screening tools that guide organ-sparing therapy in IBD patients. This review aims to summarise the existing literature on IBD-associated CRC, focusing on new insights into the alteration of the intestinal barrier and the interactions with the gut microbiome as the initial promoter. In addition, the role of OMIC techniques for precision medicine and the impact of the available IBD therapeutic armamentarium on the evolution to CRC will be discussed.https://www.mdpi.com/2072-6694/15/8/2389carcinogenesiscolitis-associated cancerinflammationIBD therapygut barrierOMIC |
| spellingShingle | Olga Maria Nardone Irene Zammarchi Giovanni Santacroce Subrata Ghosh Marietta Iacucci Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy Cancers carcinogenesis colitis-associated cancer inflammation IBD therapy gut barrier OMIC |
| title | Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy |
| title_full | Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy |
| title_fullStr | Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy |
| title_full_unstemmed | Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy |
| title_short | Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy |
| title_sort | inflammation driven colorectal cancer associated with colitis from pathogenesis to changing therapy |
| topic | carcinogenesis colitis-associated cancer inflammation IBD therapy gut barrier OMIC |
| url | https://www.mdpi.com/2072-6694/15/8/2389 |
| work_keys_str_mv | AT olgamarianardone inflammationdrivencolorectalcancerassociatedwithcolitisfrompathogenesistochangingtherapy AT irenezammarchi inflammationdrivencolorectalcancerassociatedwithcolitisfrompathogenesistochangingtherapy AT giovannisantacroce inflammationdrivencolorectalcancerassociatedwithcolitisfrompathogenesistochangingtherapy AT subrataghosh inflammationdrivencolorectalcancerassociatedwithcolitisfrompathogenesistochangingtherapy AT mariettaiacucci inflammationdrivencolorectalcancerassociatedwithcolitisfrompathogenesistochangingtherapy |